- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04862221
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH)
A Phase 2b, Double-Blind, Three Arm, Randomized, Placebo Controlled Trial With Restricted Response Adaptive Randomization Testing the Efficacy and Safety of High Dose Methylprednisolone or Equine Anti-Thymocyte Globulin as Treatment for Acute Liver Failure in Pediatric Patients
Study Overview
Status
Conditions
Detailed Description
Pediatric Acute Liver Failure (PALF) is a rare, devastating condition that affects an estimated 250 children per year in North America, causing death in approximately 15% and the need for liver transplantation in an additional 20-30%. In the majority of cases, a specific cause of the liver injury is never determined. Recent research supports the theory that many of these patients have liver injury related to a hyperinflammatory immune response to everyday infections or environmental exposures. There is strong evidence to show that equine anti-thymocyte globulin and methylprednisolone slow the body's response to inflammation and improve the recovery of patients with other immune disorders and thus, may help patients with acute liver failure.
This is a phase 2b, double-blind, three arm, randomized, placebo controlled trial with restricted response adaptive randomization. The primary objective is to determine the efficacy and safety of high-dose methylprednisolone or equine anti-thymocyte globulin (eATG or ATGAM®) as compared to supportive care alone (placebo) for the treatment of acute liver failure in pediatric patients.
Approximately 160 patients who are equal to or greater than ≥ 1 and less than ≤ 18 years of age with pediatric acute liver failure (PALF) of undetermined etiology will be randomized to receive either high-dose methylprednisolone (Treatment 1) or eATG (ATGAM®) (Treatment 2) or supportive care alone (Treatment 3) on days 1 to 4 after study enrollment, followed by a gradual prednisolone taper (for the two active treatment arms 1 and 2) or a placebo taper (for treatment arm 3) on days 5 to 42.
The follow-up period includes visits at 1 week (Day 7), 2 weeks (Day 14), and 3 weeks (Day 21) after the day the participant started in the study. Early follow-up assessments will be performed either in the inpatient or ambulatory setting since some participants may be discharged before Day 7. In addition, families will be contacted by phone or email to schedule each follow-up at the study site for the 6 week, 3 month, 6 month and 12 month study visits.
The findings of this trial have the potential to shift the treatment paradigm in PALF and advance the basic understanding of immune dysregulation disorders in childhood. The network includes 20 of the largest and most active pediatric liver centers in the US who have organized to support rigorous testing of the efficacy and safety of immunosuppressive therapy for these patients.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Katie Neighbors, MPH
- Phone Number: 312-227-4557
- Email: kneighbors@luriechildrens.org
Study Contact Backup
- Name: Monica Martino
- Phone Number: 843-876-2616
- Email: martmoni@musc.edu
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Recruiting
- Children's Hospital Los Angeles
-
Contact:
- Beth Carter, MD
- Phone Number: 323-361-5454
- Email: becarter@chla.usc.edu
-
Principal Investigator:
- Beth Carter, MD
-
Palo Alto, California, United States, 94304
- Recruiting
- Lucile Packard Children's Hospital
-
Contact:
- Amrita Narang, MD
- Phone Number: 312-498-5294
- Email: anarang@stanford.edu
-
Principal Investigator:
- Amrita Narang, MD
-
San Francisco, California, United States, 94158
- Recruiting
- University of California San Francisco Benioff Children's Hospital
-
Contact:
- Philip Rosenthal, MD
- Phone Number: 415-476-5892
- Email: prosenth@ucsf.edu
-
Principal Investigator:
- Philip Rosenthal, MD
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Recruiting
- Children's Hospital Colorado
-
Contact:
- Shikha Sundaram, MD
- Phone Number: 720-777-6669
- Email: shikha.sundaram@childrenscolorado.org
-
Principal Investigator:
- Shikha Sundaram, MD
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale New Haven Children's Hospital
-
Contact:
- Rima Fawaz, MD
- Phone Number: 203-785-4649
- Email: rima.fawaz@yale.edu
-
Principal Investigator:
- Rima Fawaz, MD
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Recruiting
- Emory Children's Healthcare of Atlanta
-
Contact:
- Rene Romero, MD
- Phone Number: 404-785-1832
- Email: Rene.Romero@choa.org
-
Principal Investigator:
- Rene Romero, MD
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Contact:
- Catherine Chapin, MD
- Phone Number: 312-227-5511
- Email: cchapin@luriechildrens.org
-
Principal Investigator:
- Catherine Chapin, MD
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Riley Hospital for Children
-
Contact:
- Kyla Tolliver, MD
- Phone Number: 317-944-3774
- Email: kmtolliv@iu.edu
-
Principal Investigator:
- Kyla Tolliver, MD
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Children's Hospital Boston
-
Contact:
- Scott Elisofon
- Phone Number: 617-355-5837
- Email: Scott.Elisosfon@childrens.harvard.edu
-
Principal Investigator:
- Scott Elisofon, MD
-
-
Missouri
-
Kansas City, Missouri, United States, 64108
- Recruiting
- The Children's Mercy Hospital
-
Contact:
- Ryan Fischer, MD
- Phone Number: 816-302-3410
- Email: rtfischer@cmh.edu
-
Principal Investigator:
- Ryan Fischer, MD
-
Saint Louis, Missouri, United States, 63110
- Recruiting
- St. Louis Children's Hospital
-
Contact:
- David Rudnick, MD PhD
- Phone Number: 314-286-2832
- Email: rudnick_d@wustl.edu
-
Principal Investigator:
- David Rudnick, MD PhD
-
-
New York
-
New York, New York, United States, 10029
- Recruiting
- The Mount Sinai Medical Center
-
Contact:
- Jaime Chu, MD
- Phone Number: 212-659-8060
- Email: Jaime.Chu@mssm.edu
-
Principal Investigator:
- Jaime Chu, MD
-
New York, New York, United States, 10032
- Recruiting
- NYP Morgan Stanley Children's Hospital
-
Contact:
- Steven Lobritto, MD
- Phone Number: 212-305-3000
- Email: sjl12@cumc.columbia.edu
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Withdrawn
- Duke University Medical Center - Duke Children's
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Recruiting
- Cincinnati Children's Hospital Medical Center
-
Contact:
- Anna Peters, MD PhD
- Phone Number: 319-321-9720
- Email: Anna.Peters@cchmc.org
-
Principal Investigator:
- Anna Peters, MD PhD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- The Children's Hospital of Philadelphia
-
Contact:
- Kathleen Loomes, MD
- Phone Number: 267-426-7223
- Email: LOOMES@email.chop.edu
-
Principal Investigator:
- Kathleen Loomes, MD
-
Pittsburgh, Pennsylvania, United States, 15224
- Recruiting
- Children's Hospital of Pittsburgh
-
Contact:
- James Squires, MD
- Phone Number: 412-692-5180
- Email: james.squires2@chp.edu
-
Principal Investigator:
- James Squires, MD
-
-
Texas
-
Dallas, Texas, United States, 75235
- Recruiting
- UT Southwestern Medical Center Children's Health
-
Contact:
- Norberto Rodriguez-Baez, MD
- Phone Number: 214-456-7436
- Email: Norberto.Rodriguez-Baez@UTSouthwestern.edu
-
Principal Investigator:
- Norberto Rodriguez-Baez, MD
-
Houston, Texas, United States, 77030
- Recruiting
- Texas Children's Hospital
-
Contact:
- Anna Banc-Husu, MD MSCI
- Phone Number: 832-822-3624
- Email: anna.banc-husu@bcm.edu
-
Principal Investigator:
- Anna Banc-Husu, MD MSCI
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Recruiting
- Primary Children's Medical Center
-
Contact:
- Kyle Jensen, MD
- Phone Number: 801-213-3599
- Email: kyle.jensen@hsc.utah.edu
-
Principal Investigator:
- Kyle Jensen, MD
-
-
Washington
-
Seattle, Washington, United States, 98105
- Recruiting
- Seattle Children's Hospital
-
Contact:
- Pamela Valentino, MD
- Phone Number: 206-987-1095
- Email: pamela.valentino@seattlechildrens.org
-
Principal Investigator:
- Pamela Valentino, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient with liver injury of ≤ 6 weeks duration resulting in an international normalized ratio (INR) of ≥ 1.5 and < 2.0 (not corrected by vitamin K) with evidence of hepatic encephalopathy (HE) or INR ≥ 2.0 without evidence of HE.
- Age is greater than or equal to 1 year and less than 18 years of age.
- Patient or their legally authorized representative(s) (LAR) must consent (and assent, if applicable) to be in the study and must have signed and dated an approved informed consent form which conforms to federal and institutional guidelines.
- Females of reproductive potential should not plan on conceiving children during the study and must agree to use a medically accepted form of contraception.
Exclusion Criteria:
- Evidence of active infection with Hepatitis A, B, C, E or evidence of acute herpes simplex virus (HSV) or adenovirus infection
- Travel within the past 3 months to an area highly endemic for Hepatitis E
- Diagnosis of hemophagocytic lymphohistiocytosis (HLH) Note: Patients with a history of consanguinity and/or central nervous system (CNS) dysfunction that is exaggerated compared to the degree of liver dysfunction (as judged by the site investigator) will not be enrolled until results of rapid genetic testing are available. Turn-around time for genetic testing results is estimated to be 72-96 hours.
- Aplastic anemia as defined by standardized criteria [1] diagnosed prior to enrollment
- Diagnosis of autoimmune Hepatitis (AIH)
- Diagnosis of acute Wilson disease
- Diagnosis of inborn error of metabolism Note: Suspicion of metabolic disease is not an exclusion for entry into the Trial.
- Diagnosis of acute drug or toxin-induced liver injury
- History of recreational drug use within the past 4 weeks
- Therapy with an immunosuppressive agent, including chemotherapy, biological therapies or an experimental drug or device within the past 6 weeks
- Liver injury due to ischemia
- Liver dysfunction diagnosed more than 6 weeks prior to screening
- History of allergy to horse dander
- Sepsis
- Imminent risk of death as judged by the clinical site investigator, including but not limited to; signs of cerebral herniation at the time of enrollment and presence of intractable arterial hypotension
- Solid organ or stem cell transplant recipient
- Pregnant or breast-feeding at the time of proposed study entry
- Clinical AIDS or HIV positive
- History of any form of malignant neoplasm and/or tumors treated within five years prior to study entry (other than non-melanoma skin cancer or in situ cervical cancer) or where there is current evidence of recurrent or metastatic disease
- Received a live-virus vaccine within 4 weeks of study entry
- Positive test result for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
- Psychiatric or addictive disorders that would preclude obtaining informed consent/assent
- Patient is unwilling or unable to adhere with study requirements and procedures
- Currently receiving other experimental therapies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: High-dose methylprednisolone
Intravenous methylprednisolone at an initial dose of 10 mg/kg/day for 3 days, 5 mg/kg/day on day 4.
|
Subjects in the high-dose methylprednisolone arm will receive an initial dose of methylprednisolone IV 10 mg/kg/day for 3 days and 5 mg/kg/day on Day 4. Normal saline will be used as placebo pre-medications and infusions given at the same volume and duration as the eATG infusions.
Other Names:
Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below. Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day) Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day) Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day) Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day) Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day) Day 42 Discontinue
Other Names:
|
Experimental: Equine anti-thymocyte globulin
Intravenous equine anti-thymocyte globulin at a dose of 40 mg/kg/day for 4 days.
|
Subjects will receive prednisolone 1 mg/kg on Days 5-13 followed by a gradual taper with discontinuation at 42 Days as indicated below. Days 5 - 13 Prednisolone PO 1 mg/kg/day (max 50 mg/day) Days 14- 20 Prednisolone PO 0.5 mg/kg/day (max 25 mg/day) Days 21 - 27 Prednisolone PO 0.3 mg/kg/day (max 15 mg/day) Days 28 - 34 Prednisolone PO 0.1 mg/kg/day (max 5 mg/day) Days 35 - 41 Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day) Day 42 Discontinue
Other Names:
Subjects will receive eATG IV 40 mg/kg/day on Days 1- 4. Day 1 eATG infusion is run over 8 hours and Day 2-4 infusions are run over 4 hours.
Other Names:
Subjects in the eATG arm will receive pre-treatment medication diphenhydramine IV 1 mg/kg prior to start of eATG infusion.
Other Names:
Subjects in the eATG arm will receive pre-treatment medication methylprednisolone IV 1 mg/kg prior to start of eATG infusion.
Other Names:
|
Placebo Comparator: Supportive care
Supportive care will be administered as determined by the clinical team at participating clinical sites in accordance with their local practices and standards.
|
Subjects will receive 1 mg/kg/day of oral placebo for prednisolone on days 5-13 followed by a gradual taper to discontinuation at 42 days as indicated below. Subjects receiving oral placebo will be given a solution that closely resembles the treatment drug. Days 5 - 13 Placebo for Prednisolone PO 1 mg/kg/day (max 50 mg/day) Days 14- 20 Placebo for Prednisolone PO 0.5 mg/kg/day (max 25 mg/day) Days 21 - 27 Placebo for Prednisolone PO 0.3 mg/kg/day (max 15 mg/day) Days 28 - 34 Placebo for Prednisolone PO 0.1 mg/kg/day (max 5 mg/day) Days 35 - 41 Placebo for Prednisolone PO 0.1 mg/kg every OTHER day (max 5 mg every other day) Day 42 Discontinue
Subjects randomized to the supportive care alone arm will receive normal saline in place of all study treatments (skin test, premedication and IV infusions) on Days 1-4 given at the same volume and duration as the eATG infusions.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival with native liver (SNL)
Time Frame: 21 days
|
Alive and without a liver transplant 21 days following randomization
|
21 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival with native liver (SNL)
Time Frame: 180 days
|
Alive and without a liver transplant 6 months (180 days) following randomization
|
180 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Estella M Alonso, MD, Ann & Robert H Lurie Children's Hospital of Chicago
- Principal Investigator: Valerie L Durkalski-Mauldin, PhD, Medical University of South Carolina
- Study Director: Ed Doo, MD, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study Director: Averell Sherker, MD, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Liver Diseases
- Brain Diseases, Metabolic
- Liver Failure
- Hepatic Insufficiency
- Hepatic Encephalopathy
- Brain Diseases
- Liver Failure, Acute
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Neuroprotective Agents
- Protective Agents
- Dermatologic Agents
- Hypnotics and Sedatives
- Anesthetics, Local
- Anti-Allergic Agents
- Sleep Aids, Pharmaceutical
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Prednisolone
- Methylprednisolone Acetate
- Methylprednisolone
- Methylprednisolone Hemisuccinate
- Prednisolone acetate
- Prednisolone hemisuccinate
- Prednisolone phosphate
- Diphenhydramine
- Promethazine
- Antilymphocyte Serum
Other Study ID Numbers
- PALF IRN/TRIUMPH
- U01DK062436 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatic Encephalopathy
-
Jinnah Postgraduate Medical CentreNot yet recruitingHepatic Encephalopathy Stage 2 | Hepatic Encephalopathy Stage 3 | Hepatic Encephalopathy Stage 4Pakistan
-
Sherief Abd-ElsalamTanta UniversityUnknownEncephalopathy, HepaticEgypt
-
Hunter Holmes Mcguire Veteran Affairs Medical CenterInstituto Grifols, S.A.; McGuire Research InstituteCompletedHepatic Encephalopathy | Cirrhosis | Minimal Hepatic Encephalopathy | Covert Hepatic EncephalopathyUnited States
-
Institute of Liver and Biliary Sciences, IndiaWithdrawnRefractory Hepatic EncephalopathyIndia
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Aga Khan UniversityUnknownEncephalopathy, Hepatic | Hepatocerebral Encephalopathy | Portal-Systemic Encephalopathy | Encephalopathy, HepatocerebralPakistan
-
Consorci Sanitari de l'Alt Penedès i GarrafWithdrawn
-
Ain Shams UniversityCompletedMinimal Hepatic Encephalopathy
-
Mansoura UniversityCompletedMinimal Hepatic EncephalopathyEgypt
-
Shanghai Changzheng HospitalEnrolling by invitationHepatic Encephalopathy | Covert Hepatic EncephalopathyChina
Clinical Trials on High-dose methylprednisolone
-
GlaxoSmithKlineTerminatedGraves OphthalmopathyUnited Kingdom
-
Children's Hospital of PhiladelphiaCompleted
-
Beijing Northland Biotech. Co., Ltd.CompletedAcute Myocardial InfarctionChina
-
National Institute of Diabetes and Digestive and...Washington University School of Medicine; University of Alabama at Birmingham; Icahn School of Medicine at Mount Sinai and other collaboratorsCompletedEnd Stage Renal DiseaseUnited States
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Baylor College of MedicineNeuroMetrix, Inc.RecruitingPain | Neuropathy | Chemotherapy-induced Peripheral NeuropathyUnited States
-
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...RecruitingSystemic Lupus ErythematosusUnited States, Spain, China, Korea, Republic of, Argentina, Bulgaria, Chile, Greece, Japan, Mauritius, Mexico, Moldova, Republic of, Poland, South Africa, Australia, Colombia, Philippines, Serbia
-
Jiangsu Kanion Pharmaceutical Co., LtdCompleted
-
Purdue UniversityAlliance for Potato Research and EducationCompletedBlood Pressure | Potassium BioavailabilityUnited States